Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis

Lindsay K. Murray, Jose González-Costello, Samual N. Jonas, Daniel B. Sims, Kerry A. Morrison, Paolo C. Colombo, Donna M. Mancini, Susan W. Restaino, Evan Joye, Evelyn Horn, Hiroo Takayama, Charles C. Marboe, Yoshifumi Naka, Ulrich P. Jorde, Nir Uriel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aims: Giant cell myocarditis (GCM) carries a poor prognosis and many patients require end-stage therapies. This study sought to determine the outcome of patients bridged with ventricular assist devices (VAD) to orthotopic heart transplantation (OHT). Methods and results: A retrospective data collection of all patients with GCM was performed. Diagnosis was determined by endomyocardial or explanted heart biopsy. Eight patients were found, but two of those patients went directly to OHT and were excluded. The remaining six patients received VADs, and these patients, aged 44 ± 18 years, were included. Five of the six patients were bridged with biventricular support and one patient was supported by left ventricular assist device (LVAD) alone. Two patients died on device support. Four patients were bridged to OHT 77 ± 42 days after device implantation. All four patients bridged with a VAD are alive, with a mean follow-up of 5.7 ± 4.1 years. Two patients were found to have recurrent GCM in the transplanted heart and were treated successfully with immunosuppression. Three patients had high grade (2R) rejection at 66 ± 52 days post-OHT. Cardiac function was preserved in all patients, and only one patient had cardiac allograft vasculopathy. Conclusion: Patients with end-stage GCM can be successfully bridged with VADs to OHT with very good post-OHT survival. The proper immunosuppressive regimen for this group needs further investigation given the frequency of rejection and GCM recurrence.

Original languageEnglish (US)
Pages (from-to)312-318
Number of pages7
JournalEuropean Journal of Heart Failure
Volume14
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Heart-Assist Devices
Myocarditis
Giant Cells
Heart Transplantation
Equipment and Supplies
Immunosuppressive Agents

Keywords

  • Giant cell myocarditis
  • Heart transplantation
  • Left ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. / Murray, Lindsay K.; González-Costello, Jose; Jonas, Samual N.; Sims, Daniel B.; Morrison, Kerry A.; Colombo, Paolo C.; Mancini, Donna M.; Restaino, Susan W.; Joye, Evan; Horn, Evelyn; Takayama, Hiroo; Marboe, Charles C.; Naka, Yoshifumi; Jorde, Ulrich P.; Uriel, Nir.

In: European Journal of Heart Failure, Vol. 14, No. 3, 03.2012, p. 312-318.

Research output: Contribution to journalArticle

Murray, LK, González-Costello, J, Jonas, SN, Sims, DB, Morrison, KA, Colombo, PC, Mancini, DM, Restaino, SW, Joye, E, Horn, E, Takayama, H, Marboe, CC, Naka, Y, Jorde, UP & Uriel, N 2012, 'Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis', European Journal of Heart Failure, vol. 14, no. 3, pp. 312-318. https://doi.org/10.1093/eurjhf/hfr174
Murray, Lindsay K. ; González-Costello, Jose ; Jonas, Samual N. ; Sims, Daniel B. ; Morrison, Kerry A. ; Colombo, Paolo C. ; Mancini, Donna M. ; Restaino, Susan W. ; Joye, Evan ; Horn, Evelyn ; Takayama, Hiroo ; Marboe, Charles C. ; Naka, Yoshifumi ; Jorde, Ulrich P. ; Uriel, Nir. / Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. In: European Journal of Heart Failure. 2012 ; Vol. 14, No. 3. pp. 312-318.
@article{9ee7cd9e2a394b6790f89e3f3e706911,
title = "Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis",
abstract = "Aims: Giant cell myocarditis (GCM) carries a poor prognosis and many patients require end-stage therapies. This study sought to determine the outcome of patients bridged with ventricular assist devices (VAD) to orthotopic heart transplantation (OHT). Methods and results: A retrospective data collection of all patients with GCM was performed. Diagnosis was determined by endomyocardial or explanted heart biopsy. Eight patients were found, but two of those patients went directly to OHT and were excluded. The remaining six patients received VADs, and these patients, aged 44 ± 18 years, were included. Five of the six patients were bridged with biventricular support and one patient was supported by left ventricular assist device (LVAD) alone. Two patients died on device support. Four patients were bridged to OHT 77 ± 42 days after device implantation. All four patients bridged with a VAD are alive, with a mean follow-up of 5.7 ± 4.1 years. Two patients were found to have recurrent GCM in the transplanted heart and were treated successfully with immunosuppression. Three patients had high grade (2R) rejection at 66 ± 52 days post-OHT. Cardiac function was preserved in all patients, and only one patient had cardiac allograft vasculopathy. Conclusion: Patients with end-stage GCM can be successfully bridged with VADs to OHT with very good post-OHT survival. The proper immunosuppressive regimen for this group needs further investigation given the frequency of rejection and GCM recurrence.",
keywords = "Giant cell myocarditis, Heart transplantation, Left ventricular assist device",
author = "Murray, {Lindsay K.} and Jose Gonz{\'a}lez-Costello and Jonas, {Samual N.} and Sims, {Daniel B.} and Morrison, {Kerry A.} and Colombo, {Paolo C.} and Mancini, {Donna M.} and Restaino, {Susan W.} and Evan Joye and Evelyn Horn and Hiroo Takayama and Marboe, {Charles C.} and Yoshifumi Naka and Jorde, {Ulrich P.} and Nir Uriel",
year = "2012",
month = "3",
doi = "10.1093/eurjhf/hfr174",
language = "English (US)",
volume = "14",
pages = "312--318",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis

AU - Murray, Lindsay K.

AU - González-Costello, Jose

AU - Jonas, Samual N.

AU - Sims, Daniel B.

AU - Morrison, Kerry A.

AU - Colombo, Paolo C.

AU - Mancini, Donna M.

AU - Restaino, Susan W.

AU - Joye, Evan

AU - Horn, Evelyn

AU - Takayama, Hiroo

AU - Marboe, Charles C.

AU - Naka, Yoshifumi

AU - Jorde, Ulrich P.

AU - Uriel, Nir

PY - 2012/3

Y1 - 2012/3

N2 - Aims: Giant cell myocarditis (GCM) carries a poor prognosis and many patients require end-stage therapies. This study sought to determine the outcome of patients bridged with ventricular assist devices (VAD) to orthotopic heart transplantation (OHT). Methods and results: A retrospective data collection of all patients with GCM was performed. Diagnosis was determined by endomyocardial or explanted heart biopsy. Eight patients were found, but two of those patients went directly to OHT and were excluded. The remaining six patients received VADs, and these patients, aged 44 ± 18 years, were included. Five of the six patients were bridged with biventricular support and one patient was supported by left ventricular assist device (LVAD) alone. Two patients died on device support. Four patients were bridged to OHT 77 ± 42 days after device implantation. All four patients bridged with a VAD are alive, with a mean follow-up of 5.7 ± 4.1 years. Two patients were found to have recurrent GCM in the transplanted heart and were treated successfully with immunosuppression. Three patients had high grade (2R) rejection at 66 ± 52 days post-OHT. Cardiac function was preserved in all patients, and only one patient had cardiac allograft vasculopathy. Conclusion: Patients with end-stage GCM can be successfully bridged with VADs to OHT with very good post-OHT survival. The proper immunosuppressive regimen for this group needs further investigation given the frequency of rejection and GCM recurrence.

AB - Aims: Giant cell myocarditis (GCM) carries a poor prognosis and many patients require end-stage therapies. This study sought to determine the outcome of patients bridged with ventricular assist devices (VAD) to orthotopic heart transplantation (OHT). Methods and results: A retrospective data collection of all patients with GCM was performed. Diagnosis was determined by endomyocardial or explanted heart biopsy. Eight patients were found, but two of those patients went directly to OHT and were excluded. The remaining six patients received VADs, and these patients, aged 44 ± 18 years, were included. Five of the six patients were bridged with biventricular support and one patient was supported by left ventricular assist device (LVAD) alone. Two patients died on device support. Four patients were bridged to OHT 77 ± 42 days after device implantation. All four patients bridged with a VAD are alive, with a mean follow-up of 5.7 ± 4.1 years. Two patients were found to have recurrent GCM in the transplanted heart and were treated successfully with immunosuppression. Three patients had high grade (2R) rejection at 66 ± 52 days post-OHT. Cardiac function was preserved in all patients, and only one patient had cardiac allograft vasculopathy. Conclusion: Patients with end-stage GCM can be successfully bridged with VADs to OHT with very good post-OHT survival. The proper immunosuppressive regimen for this group needs further investigation given the frequency of rejection and GCM recurrence.

KW - Giant cell myocarditis

KW - Heart transplantation

KW - Left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84857568426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857568426&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfr174

DO - 10.1093/eurjhf/hfr174

M3 - Article

C2 - 22265922

AN - SCOPUS:84857568426

VL - 14

SP - 312

EP - 318

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -